Is PAIOF or EQR a better dividend investment in 2026?

PAIOF currently yields 20000.00% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: PAIOF offers higher current income.

What is the dividend yield difference between PAIOF and EQR?

PAIOF has a forward dividend yield of 20000.00% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 19995.27 percentage points.

Home › Compare › PAIOF vs EQR

PAIOF vs EQR: Dividend Comparison 2026

PAIOF yields 20000.00% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PAIOF wins by $52481917574412746752.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PAIOF

● Live price

20000.00%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$52481917574412746752.00M

Annual income

$51,970,745,957,167,775,000,000,000.00

Full PAIOF calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — PAIOF vs EQR

📍 PAIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PAIOF	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PAIOF + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PAIOF pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAIOF

Annual income on $10K today (after 15% tax)

$1,700,000.00/yr

After 10yr DRIP, annual income (after tax)

$44,175,134,063,592,610,000,000,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, PAIOF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAIOF + EQR for your $10,000?

PAIOF: 50%EQR: 50%

100% EQR50/50100% PAIOF

Portfolio after 10yr

$26240958787206373376.00M

Annual income

$25,985,372,978,583,888,000,000,000.00/yr

Blended yield

99.03%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PAIOF

No analyst data

Altman Z

-10.7

Piotroski

3/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAIOF buys

EQR buys

No recent congressional trades found for PAIOF or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPAIOFEQR

Forward yield	20000.00% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$52481917574412746752.00M ✓	$40.5K
Annual income after 10y	$51,970,745,957,167,775,000,000,000.00 ✓	$3,819.61
Total dividends collected	$52448189483771600896.00M ✓	$16.9K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: PAIOF vs EQR ($10,000, DRIP)

Year	PAIOF Portfolio	PAIOF Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$2,010,700	$2,000,000.00	$11,248	$547.57	+$2.00M → PAIOF
2	$377,983,225	$375,831,775.70	$12,701	$666.53	+$377.97M → PAIOF
3	$66,433,479,469	$66,029,037,418.28	$14,405	$814.59	+$66433.47M → PAIOF
4	$10,916,985,471,987	$10,845,901,648,955.73	$16,413	$999.84	+$10916985.46M → PAIOF
5	$1,677,384,363,769,318	$1,665,703,189,314,291.80	$18,795	$1,232.92	+$1677384363.75M → PAIOF
6	$240,985,175,079,139,100	$239,190,373,809,905,920.00	$21,639	$1,527.95	+$240985175079.12M → PAIOF
7	$32,373,573,631,143,694,000	$32,115,719,493,809,017,000.00	$25,057	$1,903.80	+$32373573631143.67M → PAIOF
8	$4,066,766,648,320,630,000,000	$4,032,126,924,535,306,000,000.00	$29,197	$2,385.87	+$4066766648320630.00M → PAIOF
9	$477,730,483,406,513,300,000,000	$473,379,043,092,810,300,000,000.00	$34,250	$3,008.70	+$477730483406513344.00M → PAIOF
10	$52,481,917,574,412,750,000,000,000	$51,970,745,957,167,775,000,000,000.00	$40,467	$3,819.61	+$52481917574412746752.00M → PAIOF

PAIOF vs EQR: Complete Analysis 2026

PAIOF — Stock

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Full PAIOF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this PAIOF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAIOF vs SCHD PAIOF vs JEPI PAIOF vs O PAIOF vs KO PAIOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.